T2 Biosystems, Inc. (NASDAQ:TTOO) General Counsel Michael Terrence Gibbs sold 7,280 shares of T2 Biosystems stock in a transaction on Tuesday, February 23rd. The shares were sold at an average price of $2.06, for a total transaction of $14,996.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.
Shares of NASDAQ:TTOO traded down $0.30 during midday trading on Tuesday, reaching $2.22. The company’s stock had a trading volume of 268,886 shares, compared to its average volume of 18,414,072. The firm has a market capitalization of $328.46 million, a PE ratio of -3.32 and a beta of 0.72. T2 Biosystems, Inc. has a twelve month low of $0.23 and a twelve month high of $3.79. The stock has a fifty day moving average of $2.31 and a 200 day moving average of $1.55. The company has a quick ratio of 4.63, a current ratio of 4.97 and a debt-to-equity ratio of 2.54.
A number of analysts have recently weighed in on TTOO shares. SVB Leerink reduced their target price on shares of T2 Biosystems from $4.00 to $3.00 and set an “outperform” rating on the stock in a report on Wednesday, January 27th. Canaccord Genuity reissued a “buy” rating and issued a $3.50 price objective on shares of T2 Biosystems in a research report on Tuesday, January 26th. Jonestrading reaffirmed a “buy” rating and issued a $3.50 price target on shares of T2 Biosystems in a research report on Wednesday, January 27th. Finally, Alliance Global Partners cut shares of T2 Biosystems from a “buy” rating to a “neutral” rating and lowered their price target for the stock from $2.60 to $2.40 in a research report on Wednesday, January 27th. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. T2 Biosystems has a consensus rating of “Buy” and an average target price of $2.57.
T2 Biosystems Company Profile
T2 Biosystems, Inc, an in vitro diagnostics company, develops diagnostic products and product candidates in the United States and internationally. It provides T2 Magnetic Resonance technology that enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine.
Read More: Marijuana Stocks
Receive News & Ratings for T2 Biosystems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for T2 Biosystems and related companies with MarketBeat.com's FREE daily email newsletter.